Article Information
History
- October 25, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Yohei Funakoshi1,*,#,
- Kimikazu Yakushijin1,*,
- Goh Ohji2,
- Wataru Hojo3,
- Hironori Sakai3,
- Ryo Takai4,
- Taku Nose1,
- Shinya Ohata1,
- Yoshiaki Nagatani1,
- Taiji Koyama1,
- Akihito Kitao1,
- Meiko Nishimura1,
- Yoshinori Imamura1,
- Naomi Kiyota1,5,
- Kenichi Harada6,
- Yugo Tanaka7,
- Yasuko Mori8 and
- Hironobu Minami1,5
- 1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
- 2Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
- 3R&D, Cellspect Co., Ltd., Morioka, Japan
- 4Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
- 5Cancer Center, Kobe University Hospital, Kobe, Japan
- 6Division of Urology, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
- 7Division of Thoracic Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
- 8Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan
- ↵#Corresponding author: Yohei Funakoshi, M.D., Ph.D., Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, E-mail: yohei{at}med.kobe-u.ac.jp, Phone: +81-78-382-5820, Fax: +81-78-382-5821
↵* YF and KY contributed equally to this work.
Posted October 25, 2021.
Safety and Immunogenicity of the COVID-19 Vaccine BNT162b2 in Patients Undergoing Chemotherapy for Solid Cancer
